Emergent BioSolutions Announces Initiation of Phase Ib/II Study of TRU-016 in Combination with Bendamustine for Chronic Lymphocytic Leukemia February 1, 2011 No Comments
ROCKVILLE, Md., Jan 25, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is [...]